Abm Is An Innovative Drug Discovery And Development Company Focusing On Small Molecule Targeted Therapy For The Possible Treatments Of Brain Cancers Including Gbmas Well As Brain Metastasis From Melanomalung Cancerand Breast Cancerit Was Founded In 2015 By A Group Of Biotech And Pharmaceutical Industry Veterans With More Than 20 Years Of Experience In The Development Of Neurological Drugs And Enterprise Management From North Americasince Establishmentabm Is Building Its Broad Proprietary Pipeline Internally To Construct A Brain Medicine R&D Platform Through Collaborations With Cros And Partnersour Leading Program Abm 1310Is Highly Potent And Selective Braf Inhibitor With An Excellent Cell Permeability And Brain Penetrationthe Compound Was Designed To Address Cancers With Brafv600 Mutationbraf Mutation Happens In About 8Total Cancerssuch As Colorectal Cancermelanoma Drug Resistance And Brain Metastasisand Gliomacurrent Drugs Are Limited By Poor Brain Penetration As Potentially The Best In Classit Was Granted The Investigational New Drugindapproval In November 2019 In The Usa Clinical Trial Informationnct04190628More Information About Abm S Ongoing Abm 1310 Trial Is Available At Www Clinicaltrials Gov And On The Company Website At Www Abmtx Comabm 1310 Also Got Ind Approval By Nmpa In China In November 2021 Abm 168 Is A Potent Allosteric Mek Inhibitor With Good Cell Permeability And Bbb Penetrationour Approach Is To Combine Abm 168 With Another Oncogenic Driver Inhibitor Such As A Braf Inhibitorthe Compound Received Ind Approval By Fda In Oct2022
